Posted by Michael Wonder on 18 Jul 2025
Praxis Precision Medicines receives FDA breakthrough therapy designation for relutrigine for the treatment of seizures associated with SCN2A and SCN8A developmental and epileptic encephalopathies
17July 2025 - The breakthrough therapy designation was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies.
Praxis Precision Medicines today announced that the US FDA has granted breakthrough therapy designation for relutrigine, a sodium channel functional state modulator for paediatric use for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies.
